Literature DB >> 1686655

Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat.

N R Oakley1, A G Hayes, M J Sheehan.   

Abstract

Direct injections of muscimol into the ventral tegmental area (VTA) or substantia nigra zona reticulata (SNR) have been used to selectively stimulate the mesolimbic and nigro-striatal dopamine pathways respectively. Such injections induced locomotor activity, rearing, sniffing and in some animals an intermittent grooming response. These responses were rapid in onset, dose-related and relatively short lasting (less than 40 min). Selective increases in dopamine turnover were seen in the nucleus accumbens and in the striatum following VTA and SNR injections of muscimol (100 ng) respectively. Haloperidol inhibited the behavioural consequences of VTA and SNR injections of muscimol with similar potency (ED50S 0.01-0.03 mg/kg IP), and fluphenazine did likewise (ED50S 0.05-0.16 mg/kg IP). However, thioridazine (ED50S VTA: 1.45-2.04 mg/kg IP, SNR 8.50-9.20 mg/kg IP) and in particular clozapine (ED50S VTA: 0.24-0.58 mg/kg IP, SNR: 6.10-9.70 mg/kg IP) were more potent at inhibiting the locomotor activity and sniffing responses due to VTA rather than SNR administered muscimol. Since dopamine D2 antagonists are believed to exert their anti-psychotic effects via an action on mesolimbic dopaminergic systems, and their ability to induce extrapyramidal side effects (EPS) is thought to be due to an action on nigro-striatal dopamine systems, these results suggest that the behavioural models described can be used to predict efficacy and side-effect liability of potential neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686655     DOI: 10.1007/bf02244310

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  A simplified method of evaluating dose-effect experiments.

Authors:  J T LITCHFIELD; F WILCOXON
Journal:  J Pharmacol Exp Ther       Date:  1949-06       Impact factor: 4.030

2.  Regulation of nigro-striatal dopaminergic neurotransmission in the rat.

Authors:  A Dray; L J Fowler; N R Oakley; M A Simmonds; T Tanner
Journal:  Neuropharmacology       Date:  1977 Jul-Aug       Impact factor: 5.250

3.  Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action.

Authors:  T Ljungberg; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

Review 4.  The dopamine hypothesis of schizophrenia: a review.

Authors:  H Y Meltzer; S M Stahl
Journal:  Schizophr Bull       Date:  1976       Impact factor: 9.306

5.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

Review 6.  Which atypical antipsychotics are identified by screening tests?

Authors:  N C Moore; S Gershon
Journal:  Clin Neuropharmacol       Date:  1989-06       Impact factor: 1.592

7.  GABA in the ventral tegmental area: differential regional effects on locomotion, aggression and food intake after microinjection of GABA agonists and antagonists.

Authors:  J Arnt; J Scheel-Krüger
Journal:  Life Sci       Date:  1979-10-08       Impact factor: 5.037

8.  Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat.

Authors:  R M Hagan; B J Jones; C C Jordan; M B Tyers
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

9.  Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro.

Authors:  D R Bull; P Palij; M J Sheehan; J Millar; J A Stamford; Z L Kruk; P P Humphrey
Journal:  J Neurosci Methods       Date:  1990-04       Impact factor: 2.390

10.  Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy.

Authors:  J T Tschanz; G V Rebec
Journal:  Pharmacol Biochem Behav       Date:  1988-11       Impact factor: 3.533

View more
  4 in total

1.  Interactions between dopamine and GABA in the control of ambulatory activity.

Authors:  A Agmo; C Belzung; M Giordano
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

Review 3.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

4.  Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.

Authors:  Somayeh Jafari; Marc E Bouillon; Xu-Feng Huang; Stephen G Pyne; Francesca Fernandez-Enright
Journal:  BMC Pharmacol       Date:  2012-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.